Home > Gastroenterology > ECCO 2022 > Novel Treatment Modalities > Risankizumab more efficacious in colonic than in ileal Crohn’s disease

Risankizumab more efficacious in colonic than in ileal Crohn’s disease

Presented By
Dr Peter Bossuyt, Imelda General Hospital, Belgium
Conference
ECCO 2022
Trial
Phase 3, ADVANCE, MOTIVATE, FORTIFY
A post-hoc analysis of the phase 3 ADVANCE, MOTIVATE, and FORTIFY trials assessing risankizumab in participants with Crohn’s disease (CD) confirmed the efficacy of induction and maintenance therapies with this agent. The analysis further showed that risankizumab therapy is more efficacious in participants with CD who had colonic involvement than in those who had ileal involvement. Risankizumab is an IL-23 inhibitor under investigation for the treatment of patients with CD. Although several phase 3 trials have demonstrated the safety and efficacy of risankizumab as intravenous induction therapy and subcutaneous maintenance therapy in patients with CD, the efficacy of this therapy regarding disease location has not yet been investigated. “And we know that disease location may affect treatment outcomes of biologic therapies in CD,” explained Dr Peter Bossuyt (Imelda General Hospital, Belgium) [1,2]. Therefore, the current, post-hoc analysis u...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on